Cargando…
Cancer immunotherapy : immune suppression and tumor growth /
"This book highlights new principles of immune suppression that drive cancer, and offers radically new ideas about how therapy can be improved by attacking these principles. It provides an overview of immune escape as a critical trait in cancer and how applying specific combinations of immunoth...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego :
Elsevier/Academic Press,
[2013]
|
| Edición: | Second edition. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn847527218 | ||
| 003 | OCoLC | ||
| 005 | 20231117044901.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 130610t20132013caua ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d CDX |d UIU |d CUX |d OCLCF |d YDXCP |d GGVRL |d OCLCQ |d TEFOD |d E7B |d EMU |d EBLCP |d MYG |d Q2U |d UKDOC |d TEFOD |d MMU |d OCLCQ |d OCLCO |d OCLCA |d MERUC |d LND |d U3W |d D6H |d AU@ |d OCLCO |d OCLCQ |d MERER |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCA |d S2H |d OCLCO |d UKAHL |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 849951712 |a 851315809 |a 862573261 |a 1019915916 |a 1043065791 | ||
| 020 | |a 9780123946331 |q (electronic bk.) | ||
| 020 | |a 0123946336 |q (electronic bk.) | ||
| 020 | |z 9780123942968 |q (p-ISBN) | ||
| 020 | |z 0123942969 |q (p-ISBN) | ||
| 035 | |a (OCoLC)847527218 |z (OCoLC)849951712 |z (OCoLC)851315809 |z (OCoLC)862573261 |z (OCoLC)1019915916 |z (OCoLC)1043065791 | ||
| 050 | 4 | |a RC271.I45 | |
| 060 | 4 | |a QZ 266 | |
| 072 | 7 | |a HEA |x 039030 |2 bisacsh | |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.994061 |2 23 |
| 130 | 0 | |a Cancer immunotherapy (Prendergast) | |
| 245 | 1 | 0 | |a Cancer immunotherapy : |b immune suppression and tumor growth / |c edited by George Prendergast, Elizabeth M. Jaffee. |
| 250 | |a Second edition. | ||
| 264 | 1 | |a San Diego : |b Elsevier/Academic Press, |c [2013] | |
| 264 | 4 | |c �2013 | |
| 300 | |a 1 online resource (xxii, 655 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Online resource; title from resource home page (ebrary, viewed October 27, 2015). | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Section 1: Principles of basic immunology. Components of the immune system -- Adaptive immunity: B cells and antibodies -- Adaptive immunity: T cells and cytokines -- Dendritic cells: antigen processing and presentation -- Mucosal immunity -- Section 2: Principles of cancer immunobiology. Cancer immunoediting: from surveillance to escape -- Immunosurveillance: innate and adaptive antitumor immunity -- Immunological sculpting: natural killer-cell receptors and ligands -- Th17 cells in cancer -- Immune escape: immunosuppressive networks -- Section 3: Introduction to cancer therapeutics. Principles of cytotoxic chemotherapy -- Pharmacokinetics and safety assessment -- Monoclonal antibodies for cancer therapy and prevention: paradigm studies in targeting the neu/ERBB2/HER2 oncoprotein -- Genetic vaccines against cancer: design, testing and clinical performance -- Comprehensive immunomonitoring to guide the development of immunotherapeutic products for cancer -- Section 4: Strategies of passive and active immunotherapy. Adoptive T-cell therapy: engineering T-cell receptors -- Dendritic cell vaccines: sipuleucel-T and other approaches -- Antibodies to stimulate host immunity: lessons from ipilimumab -- Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned -- Adjuvant strategies for vaccines: the use of adjuvants within the cancer vaccine setting -- Section 5: Improving immunotherapeutic responses. Epigenetic approaches: emerging role of histone deacetylase inhibitors in cancer immunotherapy -- Molecular profiling of immunotherapeutic resistance -- Immune stimulatory features of classical chemotherapy -- Immunotherapy and cancer therapeutics: a rich partnership -- Section 6: Targeting strategies to defeat immune suppression. JAK/STAT signaling in myeloid cells: targets for cancer immunotherapy -- Tumor-associated macrophages in cancer growth and progression -- Tumor-induced myeloid-derived suppressor cells -- HyperAcute vaccines: a novel cancer immunotherapy -- Tumor exosomes and their impact on immunity and cancer progression -- Galectins: key players in the tumor microenvironment -- IDO in immune escape: regulation and therapeutic inhibition -- IDO pathway: effect on Foxp3+ Tregs and cancer -- Arginase, nitric oxide synthase, and novel inhibitors of l-arginine metabolism in immune modulation. | |
| 520 | |a "This book highlights new principles of immune suppression that drive cancer, and offers radically new ideas about how therapy can be improved by attacking these principles. It provides an overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease"--Publisher's description. | ||
| 650 | 0 | |a Cancer |x Immunotherapy. | |
| 650 | 0 | |a Antineoplastic agents |x Therapeutic use. | |
| 650 | 0 | |a Tumors |x Immunological aspects. | |
| 650 | 1 | 2 | |a Neoplasms |x therapy |0 (DNLM)D009369Q000628 |
| 650 | 2 | 2 | |a Antineoplastic Agents |x therapeutic use |0 (DNLM)D000970Q000627 |
| 650 | 2 | 2 | |a Immunotherapy |x methods |0 (DNLM)D007167Q000379 |
| 650 | 6 | |a Cancer |x Immunoth�erapie. |0 (CaQQLa)201-0168739 | |
| 650 | 6 | |a Anticanc�ereux |0 (CaQQLa)201-0004692 |x Emploi en th�erapeutique. |0 (CaQQLa)201-0373975 | |
| 650 | 6 | |a Tumeurs |x Immunologie. |0 (CaQQLa)201-0049657 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x Cancer. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a Cancer |x Immunotherapy |2 fast |0 (OCoLC)fst00845386 | |
| 650 | 7 | |a Antineoplastic agents |x Therapeutic use |2 fast |0 (OCoLC)fst00810609 | |
| 650 | 7 | |a Tumors |x Immunological aspects |2 fast |0 (OCoLC)fst01158775 | |
| 700 | 1 | |a Prendergast, George C., |e editor. | |
| 700 | 1 | |a Jaffee, Elizabeth M., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Cancer immunotherapy. |b Second edition. |d Amsterdam : Elsevier/Academic Press, [2013] |z 9780123942968 |w (DLC) 2013444865 |w (OCoLC)864382500 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780123942968 |z Texto completo |